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Prospective Controlled Protocol for Three Months Steroid 
Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate 
Mofetil in Renal Transplant Recipients
During the past few years, new immunosuppressants, such as tacrolimus, mycophenolate 
mofetil (MMF) and basiliximab, have been shown to successfully decrease the incidence of 
acute rejection, possibly acting as potent substrates for safe steroid withdrawal. Therefore, 
clinical outcome of 3 months steroid withdrawal, while using the above immunosuppressants, 
was analyzed. Clinical trial registry No. was NCT 01550445. Thirty de novo renal transplant 
recipients were enrolled, and prednisolone was slowly withdrawn 3 months post-
transplantation by 2.5 mg at every two weeks, until 8 weeks. During steroid withdrawal, 
10 patients (30.0%) discontinued the protocol and they were maintained on steroid 
treatment. Among 20 steroid free patients, 8 patients (40.0%) re-started the steroid within 
12 months post-transplantation. By the study endpoint, 12 (40%) recipients did not take 
steroid and survival of patients and grafts was 100%. In conclusion, in kidney transplant 
patients, 3 months steroid withdrawal while taking tacrolimus, basiliximab and 
mycophenolate mofetil was not associated with increased mortality or graft loss. Despite 
various causes of failure of steroid withdrawal during the follow-up period, it is a strategy 
well advised for kidney transplant recipients with regard to long-term steroid-related 
complications. 
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INTRODUCTION
Although corticosteroids have played an important part in the 
maintenance of immunosuppression after kidney transplanta-
tion, they are associated with debilitating adverse effects, includ-
ing diabetes, osteoporosis, cataracts, hypertension, hyperlipid-
emia, obesity, avascular necrosis, mood and appearance changes 
and growth retardation in children (1). The treatment of these 
steroid-related side effects adds to the cost of transplants. In ad-
dition, such side effects increase post-transplant non-compli-
ance, which is associated with increased incidence of acute re-
jection, chronic allograft nephropathy and graft loss. Given the 
fact that patients’ death with functioning graft was an important 
cause of graft loss after kidney transplantation (accounting for 
42.5% of graft losses in one registry analysis), and that the lead-
ing cause of death with functioning graft was cardiovascular dis-
ease, cardiovascular risk factors appear to be the most impor-
tant challenge to further improving the longevity of patients with 
successful renal transplants (2). Many of risk factors for cardio-
vascular diseases overlap with the side effects of corticosteroids, 
such as diabetes, hypertension, hyperlipidemia and weight gain. 
In order to increase the patient survival after kidney transplan-
tation, it is imperative to avoid or at least reduce such risk fac-
tors, as well as reduce the use of corticosteroids, without increas-
ing the incidence of acute rejection of the kidney graft. 
  During the past few years, new immunosuppressants, such 
as tacrolimus, mycophenolate mofetil (MMF) and basiliximab, 
have been proven to decrease the incidence of acute rejection, 
possibly acting as potent substrates for safe steroid-free immu-
nosuppression or steroid withdrawal. After transplantation, the 
major concern with any immunosuppression withdrawal pro-
tocol is the increased risk of acute and chronic rejection, poten-
tially leading to graft damage and dysfunction or loss. Therefore, 
the goal of steroid withdrawal protocols is to eliminate steroid-
related side-effects, while not increasing the rates of acute rejec-
tion or chronic graft loss. Development of more effective immu-
nosuppressive agents has led to renewed attempts at steroid 
withdrawal after kidney transplantation (3). One of meta-anal-
yses about the steroid withdrawal protocols applied between       
7 days and 12 months post-transplantation reported that the 
incidence of acute rejection was increased; however, the graft 
and patient survival was not altered, and there was marked re-Oh C-K, et al.  •  Steroid Withdrawal and Renal Transplantation
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duction in cardiovascular risk factors (4). Although there are 
many controversies about the clinical outcome after steroid avoid-
ance or withdrawal, it is generally associated with higher rate of 
steroid-sensitive acute rejections, while avoiding steroid-relat-
ed adverse effects. In regards with the interval between the ste-
roid withdrawal and the transplantation, it is generally recog-
nized that earlier steroid avoidance or withdrawal after trans-
plantation is associated with higher rate of acute graft rejection 
and with lower rate of steroid-related adverse effects for the pa-
tient. Another recent meta-analysis demonstrated that steroid 
withdrawal performed between 3 and 6 months after renal trans-
plantation was found to increase the incidence of acute rejec-
tion in patients on cyclosporine, but not tacrolimus, whereas 
no impact on graft and patient survival was reported (5). 
  In the present study, we analyzed clinical outcomes of kidney 
transplantation recipients on steroid withdrawal protocol ap-
plied 3 months after renal transplantation, using tacrolimus, 
MMF and basiliximab, and also compared clinical characteris-
tics of patients in whom corticosteroids were successfully with-
drawn with those of patients in whom corticosteroids had to be 
reinitiated because of acute rejection or other problems.
MATERIALS AND METHODS
Study design
This study was an open-label, prospective, controlled clinical 
trial at a single center, with withdrawal of steroid at 3 months 
after renal transplantation. In this 12-month study, 30 de novo 
renal transplant recipients who gave written informed consent 
were enrolled. 
Patient population
Patients older than 13 yr who received primary kidney trans-
plant from a deceased or living donor were eligible for the study. 
The exclusion criteria comprised receipt of a kidney from a do-
nor with positive lymphocyte cross-match, an ABO incompati-
ble donor, current hepatitis B or C, HIV positive, neutrophil count 
less than 500/μL, WBC count less than 1,000/μL, hemoglobin 
less than 5 g/dL, platelet count less than 30,000/μL, any mental 
disorders, any malignant disease and pregnant or lactating re-
cipients.
Immunosuppression
Tacrolimus (Tacrobell
®, Chong Kun Dang, Seoul, Korea) was 
initiated one day prior to transplantation, at 0.1 mg/kg orally 
twice a day. The target trough blood levels of tacrolimus were 
10-15 ng/mL within 3 months post-transplantation and 5-10 
ng/mL thereafter. MMF was given at a dose of 1 to 2 g/day. All 
recipients received 20 mg of basiliximab just prior to transplant 
and 4 days after transplantation. In the immunosuppressive 
protocol, methyl-prednisolone was injected with the following 
doses; 500 mg on the day of operation, 250 mg on the day after, 
125 mg on day 2, and 60 mg on day 3. Prednisolone given at a 
dose of 30 mg/day on day 4 was slowly tapered to the mainte-
nance dose of 10 mg/day by the end of the first month. The dose 
of 10 mg prednisolone a day was maintained until 3 months       
after kidney transplantation.
Steroid withdrawal at 3 months post-transplantation
Those patients who fulfilled the entry criteria were enrolled in 
this prospective controlled trial of steroid withdrawal 3 months 
after transplantation. The entry criteria were, as follows: 1) no 
episode of clinically treated or biopsy confirmed acute rejection 
prior to study entry; 2) serum creatinine level equal to or less 
than 2 mg/mL on 3 separate measurements; 3) no proteinuria 
(i.e., urine protein less than 1,000 mg/24 hr); 4) tacrolimus 
trough level  > 5 ng/mL, without signs of nephrotoxicity; and 5) 
agreement to the projected protocol follow-up. 
  For the patients who entered the protocol, prednisolone was 
slowly withdrawn by 2.5 mg every 2 weeks, until 8 weeks after 
entering the protocol (i.e., 5 months post-transplantation). The 
patients visited the center every week and were closely moni-
tored for symptoms and signs, blood cell count, chemistry and 
urinalysis. 
Evaluation
Study visits took place at baseline before transplantation, every 
day until 2 weeks post-transplantation, then every week until       
5 months post-transplantation, including regular monitoring of 
vital signs, adverse events, serious adverse events, hematology 
and blood chemistry. At 6 months post-transplantation, urine 
samples for 24 hr were collected from all recipients to analyze 
the creatinine clearance and urinary protein excretion; urine 
and serum were both checked for BK (polyoma) virus using PCR. 
Biopsy was performed in cases of deteriorating graft function 
without any obvious pre- or post-renal causes. Biopsy samples 
were examined by the pathology specialist and were classified 
in agreement with the 1997 Banff criteria.
Study endpoints
The primary efficacy variable was the incidence of biopsy-con-
firmed acute rejection. Secondary efficacy variables included 
the cumulative incidence of composite endpoint of death and 
graft loss; patient and graft survival at month 12; and the per-
centage of patients free of steroids at month 6 and 12. Safety vari-
ables included the incidence of adverse events and serious ad-
verse events, blood pressure, lipid levels (total cholesterol), blood 
urea nitrogen (BUN) and blood glucose levels. 
Statistical analysis
Statistical analyses were performed using Statistical Package for 
the Social Services (SPSS version 11.0.1) (SPSS Inc., Chicago, IL, Oh C-K, et al.  •  Steroid Withdrawal and Renal Transplantation
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USA). Student’s t-test was used to compare continuous variables 
of patient characteristics and chi-square test was used to deter-
mine categorical demographic variables and outcome differ-
ences. Continuous variables are expressed as mean ± standard 
deviation (SD). At 6 and 12 months, the actual patient and graft 
survival were reported as life-table estimates. Initiation of main-
tenance steroids at any time after 3 months post-transplanta-
tion was considered as failure of treatment. 
Ethics statements
The study was conducted in full compliance with the amended 
Declaration of Helsinki, following approval from the institutional 
review board of Ajou University Hospital (AJIRB-CRO-08-067). 
All of the 30 subjects enrolled in this study gave written informed 
consents for not only for the transplant surgery but also for this 
clinical trial prior to kidney transplantation. 
RESULTS
Subject characteristics
Between May 2008 and October 2009, 30 patients were enrolled 
in the study. Study sample is summarized in Table 1. Twenty-
two patients (73.3%) received kidneys from deceased donors 
and 8 patients (26.7%) from living donors. At 3 months post-trans-
plantation, only 3 patients (10%) discontinued the study pre-
maturely because of serum creatinine level higher than 2.0 mg/
dL, without an episode of rejection, and 27 patients (90%) con-
tinuously followed the steroid withdrawal protocol and were 
included in the intent to treat (ITT) group in the study.
Causes of failure of steroid withdrawal
During steroid withdrawal, between 3 and 5 months post-trans-
plantation, 7 patients (26.0%) discontinued the protocol and 
were maintained on steroid treatment by the following reasons: 
1 patient withdrew the written consent, 1 patient with acute re-
jection Banff IA, 2 patients with borderline changes on the bi-
opsy, 1 patient with steroid withdrawal symptoms and 2 patients 
with BK virus PCR positive. Among 20 patients with steroid free 
immunosuppression with tacolimus and MMF, 8 patients (40.0%) 
re-started the steroid for the following reasons: 2 patients with 
borderline changes on the biopsy, 5 patients with BK virus PCR 
positive, and 1 patient with CMV disease within a year post-
transplantation (Fig. 1). The overall causes of failure for steroid 
withdrawal within 1 year post-transplantation are summarized 
in Table 2.
Episodes of rejection or borderline change
Within 3 months post-transplantation, none of the patients had 
acute rejection. During the steroid withdrawal, between 3 and  
6 months post-transplantation, 1 patient (3.7% of ITT group) 
had biopsy-confirmed acute rejection (Banff IA) and 2 patients 
(7.4%) had borderline change on the biopsy. Two out of 20 com-
pletely steroid-free patients (10.0%) had borderline change on 
the graft biopsy within 1 yr post-transplantation. All patients 
Table 1. Baseline demographic characteristics of recipients and donors
Parameters  Recipients   Donors
Age (yr)   43.0 ± 9.3     45.3 ± 11.0
Gender (M:F) 46.7:53.3 63.3:36.7
Weight (kg)     58.7 ± 13.2     64.4 ± 12.5
Height (cm) 161.4 ± 6.5 164.7 ± 9.0
BMI (kg/m
2)   22.4 ± 4.1   23.7 ± 4.9
Cause of end-stage renal disease (%)
   Glomerulonephritis
   Diabetes mellitus
   Hypertensive
   Other/unknown
 
  6 (20.0)
  3 (10.0)
1 (3.3)
20 (66.7)
 
Degree of HLA mismatches (%)
   0
   1
   2
   3
   4
   5
   6
 
2 (6.7)
1 (3.3)
1 (3.3)
  8 (26.7)
  7 (23.3)
  9 (30.0)
2 (6.7)
 
Kidney transplantation
Post-transplant  
3 months
Post-transplant  
6 months
Post-transplant  
1 yr
   12 patients (60%)
   keep avoiding steroid
   3 patients serum creatinine > 2.0 mg/dL
   without an episode of rejection
   2 patients with borderline change
   5 patients with BK virus related
   1 patient with CMV virus related
   1 patient withdrawn the consents
   1 patient with acute rejection IA
   2 patients with borderline change
   1 patient with steroid withdrawal symptom
   2 patients with BK virus related
   27 patients (90%)
   start tapering steroid
   20 patients (74.1%)
   withdrawn successfully
30 patients enrolled
Fig. 1. Flowchart showing periodic causes of failure of steroid withdrawal.
Table 2. Overall causes of the failure of steroid withdrawal within 1 yr post-transplan-
tation 
Causes of failure No. (%)
Serum creatinine  > 2 mg/dL at 3 months post-transplantation 3 (10)
Consent withdrawn 1 (3.3)
Rejection or borderline change   5 (16.7)
Symptomatic adrenal insufficiency 1 (3.3)
BK virus PCR positive   7 (23.3)
CMV disease 1 (3.3)
Overall 18 (60.0)Oh C-K, et al.  •  Steroid Withdrawal and Renal Transplantation
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with acute rejection or borderline change required re-introduc-
tion of oral steroid, without steroid pulse therapy, and respond-
ed to the steroid re-introduction.
Graft function and patient survival 
At 12 months after transplantation, survival of the patients and 
grafts was 100%. Serum creatinine levels of 30 patients at 3 
months, 6 months, and 12 months post-transplantation were 
1.33 ± 0.43 mg/dL, 1.47 ± 0.44 mg/dL and 1.55 ± 0.49 mg/dL, 
respectively. Estimated GFR by MDRD (Modification of Diet in 
Renal Disease) at 3 months, 6 months, and 12 months post-trans-
plantation were 58.9 ± 16.4 mL/min, 53.2 ± 17.9 mL/min, and 
49.7 ± 16.0 mL/min, respectively. At 12 months post-transplan-
tation, among 27 ITT patients, the serum creatinine levels of 12 
cases in the withdrawn group were not statistically different 
from those of 15 cases in the steroid re-start group (1.35 ± 0.18 
mg/dL vs 1.57 ± 0.54 mg/dL, P = 0.197). The estimated GFR at 
12 months post-transplantation was higher in the withdrawn 
group than in the re-start group (58.8  ± 11.1 mL/min/1.73 m
2, 
vs 46.5 ± 16.1 mL/min/1.73 m
2, P = 0.033) (Table 3).
Physiologic variables, laboratory values and 
immunosuppression for ITT patients group at 1 yr post-
transplantation 
Table 3 shows the physiologic variables, laboratory values and 
immunosuppression in the investigated groups. There were no 
significant differences between the groups in systolic blood pres-
sure, diastolic blood pressure, mean blood pressure, body weight, 
WBC count, hemoglobin, platelet count, serum creatinine and 
serum glucose (P > 0.05, independent t-test) . Total cholesterol 
in the steroid withdrawn group was 158.0 ± 50.3 mg/dL, which 
was significantly lower than that of the steroid re-start group 
186.8 ± 34.6 mg/dL (P = 0.048, independent t-test). Similarly, 
BUN in the steroid withdrawn group was 18.8 ± 4.8 mg/dL, 
which was also significantly lower than that of the steroid re-start 
group 24.2 ± 6.9 mg/dL (P = 0.034, independent t-test). The se-
rial changes of mean cholesterol and mean BUN at 3 months,   
6 months, and 12 months post-transplantation in the different 
Table 3. Physiologic variables, laboratory values, and immunosuppression for each patient group at 1 yr post-transplantation (mean ± SD) 
Variables Steroid withdrawn (n = 12) Steroid re-start (n = 15)   P value
Systolic BP (mmHg) 128.7 ± 12.5 130 ± 13.4 0.793
Diastolic BP (mmHg) 77.8 ± 8.8 82.2 ± 11.4 0.277
Mean BP (mmHg) 94.7 ± 7.7 98.1 ± 11.1 0.375
Body weight (kg) 58.3 ± 10.0 51.3 ± 9.0 0.068
WBC count ( × 1,000/µL) 50 ± 1.7 6.0 ± 2.6 0.229
Hemoglobin (g/dL) 12.9 ± 1.7 11.6 ± 3.3 0.236
Platelet count ( × 1,000/µL) 237.4 ± 81.9 204.1 ± 53.1 0.224
Serum creatinine (mg/dL) 1.35 ± 0.18 1.57 ± 0.54 0.197
eGFR (mL/min/1.73 m
2) 58.8 ± 11.1 46.5 ± 16.1 0.033
Serum glucose (mg/dL) 108.8 ± 21.2 113.4 ± 17.9 0.555
BUN (mg/dL) 18.8 ± 4.8 24.2 ± 6.9 0.034
Cholesterol (mg/dL) 158.0 ± 50.3 186.8 ± 34.6 0.048
Tacrolimus trough level (ng/mL) 10.54 ± 3.22 9.81 ± 2.90 0.547
Tacrolimus dose (mg/day) 5.8 ± 2.8 5.5 ± 2.7 0.733
Tacrolimus dose (mg/kg/day) 0.104 ± 0.054 0.109 ± 0.064 0.836
MMF dose (mg/day) 1,500 ± 426 550 ± 584 < 0.001
Steroid dose (mg/day) 0 ± 0 8.2 ± 3.5 < 0.001
BP, blood pressure; WBC, white blood cell; eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; MMF, mycophenolate mofetil.
Fig. 2. The serial changes of mean cholesterol and mean BUN levels at 3, 6, and 12 months post-transplantation in the steroid withdrawn (n = 12) and re-start (n = 15) groups.
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groups are shown in Fig. 2. 
Adverse events
Adverse events in the ITT patients between 3 and 12 months 
post-transplantation (i.e. beyond the starting point of steroid 
withdrawal) were, as follows: 8 cases of alopecia, 7 cases of up-
per respiratory infection, 11 cases of gastrointestinal symptoms, 
4 cases of leukocytopenia ( < 3,000/μL), 2 cases of transient head-
ache, 2 cases of oral ulcer and 1 case of fatigue. serious adverse 
events (SAEs), which required to maintain the dose of steroid 
or needed either to discontinue or decrease the dose of MMF, 
were as follows: 5 cases of acute rejection or borderline change 
on biopsy, 7 cases of urinary BK virus PCR-positive, 1 case of 
CMV, and 1 case of severe steroid withdrawal symptoms, as 
shown in Fig. 1.  
DISCUSSION
Until recently, corticosteroids had been the mainstay of kidney 
transplant immunosuppressive protocols. However, well-known 
side effects of corticosteroids have increased the interest in ste-
roid-withdrawal immunosuppression for kidney transplant re-
cipients, and the goal of steroid minimization protocols has 
been to eliminate or minimize steroid-related side-effects, while 
not increasing the rates of acute rejection or graft loss. It is wide-
ly believed that the safety of steroid-free immunosuppression 
has improved the quality of life of kidney recipients since the 
mid-1990s, with the availability of tacrolimus and MMF and es-
pecially, with the regular use of induction antibody therapy.
  Hricik (6) showed that withdrawal of steroid in early phase 
after renal allograft transplantation was dangerous and could 
lead to clinical acute rejection with an incidence of 30% to 50%. 
With the development of many immunosuppressants, such as 
tacrolimus, MMF and basilixumab, some regimens have been 
demonstrated to be effective (7-9). Our present study demon-
strated that one patient (3.7% of ITT population) had an episode 
of biopsy-confirmed acute rejection (Banff IA) and 4 patients 
(14.8% of ITT population) had borderline changes on the graft 
biopsy within 1 yr post-transplantation. Five patients with acute 
rejection or borderline change were treated easily with oral 
dose of steroid and were maintained on steroid during the fol-
low-up period. Given the fact that only 5 patients (16.7% of en-
rolled subjects) had either biopsy-confirmed acute rejection or 
borderline change on the graft biopsy, the incidence of acute 
rejection within a year after transplantation was lower than that 
in previous reports. Furthermore, the fact that neither patient 
death nor graft loss occurred within 1 yr post-transplantation in 
our study population strongly suggests that steroid can safely 
be withdrawn from tacrolimus, basilixumab and MMF-treated 
renal allograft recipients. The reason that steroid can be with-
drawn could partly be explained by the special relationship be-
tween FK binding protein 52 (FKBP-52) and glucocorticoid re-
ceptor compound (GCR) (10). The incidence of acute renal 
transplant rejection has dramatically decreased over the past 
decades, with most centers reporting incidence rates between 
10% and 20% (11). After trial or completion of steroid withdraw-
al, the overall incidence of acute rejection was 16.7%, which 
was not higher than that of the kidney transplant population on 
steroids. Therefore, the strategy of steroid withdrawal could not 
increase the incidence of acute rejection.
  Previously, one study demonstrated that 33% of kidney re-
cipients had urinary BK virus PCR positivity, with or without 
clinical manifestations, such as positive Decoy cell and decrease 
of graft function (12). Our data showed that 23.3% of the study 
population had urinary BK virus PCR positivity either during or 
after steroid withdrawal. Therefore, in terms of BK virus nephrop-
athy, the strategy of steroid withdrawal could not increase the 
incidence of urinary BK virus PCR positivity.
  The lowering of cholesterol levels has been reported to be 
one of the benefits resulting from the withdrawal of steroid ther-
apy (13, 14). Furthermore, reduction of blood pressure has also 
been reported (15), albeit not unanimously (13, 14). Even though 
we were unable to demonstrate any reduction of blood pres-
sure in our patient population, steroid withdrawal immunosup-
pression significantly reduced total cholesterol level at 1 yr post-
transplantation. Noteworthy, our finding that steroid withdrawal 
immunosuppression significantly reduced the blood urea nitro-
gen (BUN) at 1 yr post-transplantation could be comparable to 
the previous report that corticosteroid could disproportionally 
increase BUN levels (16). The study results demonstrated that 
the mean eGFR of the steroid withdrawn group was significantly 
higher than that of the other group. This mainly reflected the 
fact that the subject population of the steroid withdrawn group 
consisted of patients who underwent the uneventful course after 
kidney transplantation, whereas the other group included pa-
tients with acute rejection, BK virus nephropathy or CMV infec-
tion.
  One of the limitations of our study was that it was a single-
center analysis. The pros and cons of single-center versus mul-
ticenter reports are well known. Nevertheless, our study has the 
advantage of being coordinated by a small group of people with 
well-defined decision-making protocol and patient care algo-
rithm. Because we applied our protocol to 30 transplant recipi-
ents, additional studies in larger number of kidney recipients 
should be necessary. The second limitation was that we did not 
perform protocol biopsies. Although mean creatinine levels re-
mained unchanged in our patient population, there was the 
possibility that we failed to observe some progressive fibrosis 
due to the absence of prednisone maintenance therapy. The 
third limitation was that our study was not randomized, because 
we started with a pilot study. However, in accordance with our 
present findings, the 12-month results of a prospective random-Oh C-K, et al.  •  Steroid Withdrawal and Renal Transplantation
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ized study (17), in which 364 kidney transplant recipients (on 
tacrolimus and MMF) received either two doses of anti-IL-2 re-
ceptor antibody (daclizumab) plus 3 days of prednisone or ste-
roids for 16 weeks, found no difference in the incidence of bi-
opsy-proven acute rejection between the two groups (15% in 
the dacrlizumab group vs 14% in the control group) (17). The 
fourth limitation was that long-term benefits of steroid with-
drawal were not assessed with regard to well documented com-
plications, such as cardiovascular disease and osteoporosis, be-
cause it was beyond the scope of our study. 
  In conclusion, this study confirmed that steroid withdrawal 
at 3 months post-transplantation, while using tacrolimus, basil-
iximab and MMF in kidney transplantation, was not associated 
with increased mortality or graft loss. In spite of various causes 
of failure of steroid withdrawal during the follow-up period, ste-
roid withdrawal after 3 months post-transplantation is a strategy 
well advised for kidney transplant recipients, because it could 
provide beneficial effects on short-term steroid-related compli-
cations, such as increased cholesterol and uremia and, possi-
bly, on long-term steroid-related complications.
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